186 related articles for article (PubMed ID: 38326910)
1. DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications.
Jing X; Qin X; Liu H; Liu H; Wang H; Qin J; Zhang Y; Cao S; Fan X
Eur J Med Res; 2024 Feb; 29(1):107. PubMed ID: 38326910
[TBL] [Abstract][Full Text] [Related]
2. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
[TBL] [Abstract][Full Text] [Related]
4. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome.
Na JC; Nagaya N; Rha KH; Han WK; Kim IY
Clin Genitourin Cancer; 2019 Aug; 17(4):299-305.e1. PubMed ID: 31204211
[TBL] [Abstract][Full Text] [Related]
5. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
[TBL] [Abstract][Full Text] [Related]
7. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract][Full Text] [Related]
9. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.
Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL
Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528
[TBL] [Abstract][Full Text] [Related]
10. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of prognostic and tumor microenvironment characteristics of necroptosis index and BIRC3 in clear cell renal cell carcinoma.
Wei K; Zhang X; Yang D
PeerJ; 2023; 11():e16643. PubMed ID: 38130918
[TBL] [Abstract][Full Text] [Related]
12. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.
Lin H; Qu L; Chen G; Zhang C; Lu L; Chen Y
Eur J Med Res; 2023 Jul; 28(1):236. PubMed ID: 37452355
[TBL] [Abstract][Full Text] [Related]
15. Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma.
Meng H; Jiang X; Cui J; Yin G; Shi B; Liu Q; Xuan H; Wang Y
Biomed Res Int; 2020; 2020():2495157. PubMed ID: 33062672
[TBL] [Abstract][Full Text] [Related]
16. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
[TBL] [Abstract][Full Text] [Related]
17. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
18. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
Zhang C; Li Z; Qi F; Hu X; Luo J
Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
[TBL] [Abstract][Full Text] [Related]
19. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]